Seminars in Oncology
Volume 33, Issue 6 , Pages 647-649 , December 2006

Tamoxifen in Ductal Carcinoma In Situ

  • Mary B. Daly

      Affiliations

    • Corresponding Author InformationAddress correspondence to Mary B. Daly, MD, PhD, Senior Vice President For Population Science, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111.

References 

  1. Allred D. Biologic characteristics of ductal carcinoma in situ. In:  Silverstein M editors. Ductal Carcinoma In Situ of the Breast (ed 2). Philadelphia, PA: Lippincott Williams & Wilkins; 2002;p. 37–48
  2. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomized controlled trial. Lancet. 2000;353:1993
  3. Cuzick J. Treatment of DCIS—Results from clinical trials. Surg Oncol. 2003;12:213–219
  4. Fisher B, Land S, Mamounas E, et al. Prevention of invasive breast cancer in women with ductal carcinoma in situ: An update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol. 2001;28:400–418
  5. Barnes NLP, Boland GP, Davenport A, et al. Relationship between hormone receptor status and tumor size, grade and comedo necrosis in ductal carcinoma in situ. Br J Surg. 2005;92:429–434
  6. Sakorafas GH, Farley DR. Optimal management of ductal carcinoma in situ of the breast. Surg Oncol. 2003;12:221–240
  7. Solin LJ, Kurtz J, Fourquet A, et al. Fifteen-year results of breast-conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast. J Clin Oncol. 1996;14:754–763
  8. Kerlikowske K, Molinaro A, Cha I, et al. Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst. 2003;95:1692–1702
  9. Allred DC, Bryant J, Land S, et al. Estrogen receptor expression as a predictive marker of the effectiveness of tamoxifen in the treatment of intraductal breast cancer: findings of the NSABP Protocol B-24. Breast Cancer Res Treat. 2002;77:S36;(suppl 1, abstr)
  10. UK Coordinating Committee on Cancer Research (UKCCCR) Ductal Carcinoma In Situ (DCIS) Working Party. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: Randomized controlled trial. Lancet. 2003;362:95–102
  11. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97:1652–1662
  12. Claus EB, Chu P, Howe CL, et al. Pathobiologic findings in DCIS of the breast: morphologic features, angiogenesis, HER-2/neu and hormone receptors. Exp Mol Pathol. 2001;70:303–316
  13. Albonico G, Querzoli P, Ferretti S, et al. Biological profile of in situ breast cancer investigated by immunohistochemical technique. Cancer Detect Prev. 1998;22:313–318
  14. Collins LC, Schnitt SJ. HER2 protein overexpression in estrogen receptor-positive ductal carcinoma in situ of the breast: Frequency and implications for tamoxifen therapy. Mod Pathol. 2005;18:615–620
  15. Nakhlis F, Lazarus L, Hou N, et al. Tamoxifen use in patients with ductal carcinoma in situ and T1a/b N0 invasive carcinoma. J Am Coll Surg. 2005;201:688–694
  16. Yen TWF, Hunt KK, Mirza NQ, et al. Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ. Cancer. 2004;100:942–949
  17. Port ER, Montgomery LL, Heerdt AS, et al. Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol. 2001;8:580–585

PII: S0093-7754(06)00330-7

doi: 10.1053/j.seminoncol.2006.08.019

Seminars in Oncology
Volume 33, Issue 6 , Pages 647-649 , December 2006

Article Tools